{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:58:56Z","timestamp":1780948736212,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08315"],"award-info":[{"award-number":["22K08315"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Evocalcet is an allosteric modulator of the calcium-sensing receptor (CaSR) that effectively suppresses parathyroid hormone (PTH) secretion in both primary and secondary hyperparathyroidism. However, its effects on the PTH-calcium setpoint and parathyroid cell proliferation remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated these effects using the PC mouse model of primary hyperparathyroidism, which is characterized by parathyroid-targeted cyclin D1 overexpression . Evocalcet was administered orally at a dose of 0.025 mg\/g diet. The PTH-calcium setpoint was evaluated, and the antiproliferative effect of evocalcet on parathyroid cells was assessed using 5-bromo-2\u2032-deoxyuridine (BrdU) incorporation assays. The effects of evocalcet were compared with those of cinacalcet. Expression levels of the vitamin D receptor (VDR) and CaSR in parathyroid glands were also examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Evocalcet significantly reduced the PTH-calcium setpoint in PC mice, restoring it to levels comparable to those observed in wild-type controls. Evocalcet treatment markedly decreased the proportion of BrdU-positive parathyroid cells, indicating suppression of parathyroid cell proliferation. This antiproliferative effect was comparable to that observed with cinacalcet. Neither evocalcet nor cinacalcet altered VDR or CaSR expression in the parathyroid glands.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Evocalcet, similar to cinacalcet, lowers the PTH-calcium setpoint and inhibits parathyroid cell proliferation in a mouse model of primary hyperparathyroidism. These findings suggest that evocalcet may not only reduce PTH secretion but also attenuate disease progression in hyperparathyroidism.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00774-026-01699-y","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T10:39:49Z","timestamp":1771324789000},"page":"302-311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evocalcet improved the PTH\u2013calcium setpoint and suppressed parathyroid proliferation in mice model of primary hyperparathyroidism"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9077-2631","authenticated-orcid":false,"given":"Yasuo","family":"Imanishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoe","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waka","family":"Haruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Tsushida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Kitayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehisa","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Donoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikue","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Kurajoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"1699_CR1","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1111\/j.1744-9987.2009.00768.x","volume":"13","author":"Y Imanishi","year":"2009","unstructured":"Imanishi Y, Inaba M, Kawata T, Nishizawa Y (2009) Cinacalcet in hyperfunctioning parathyroid diseases. Ther Apher Dial 13:S7\u2013S11","journal-title":"Ther Apher Dial"},{"key":"1699_CR2","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1093\/ndt\/14.10.2398","volume":"14","author":"F Malberti","year":"1999","unstructured":"Malberti F, Farina M, Imbasciati E (1999) The pth-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism. Nephrol Dial Transpl 14:2398\u20132406","journal-title":"Nephrol Dial Transpl"},{"key":"1699_CR3","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1210\/jcem-56-3-572","volume":"56","author":"EM Brown","year":"1983","unstructured":"Brown EM (1983) Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 56:572\u2013581","journal-title":"J Clin Endocrinol Metab"},{"key":"1699_CR4","first-page":"1598","volume":"81","author":"O Kifor","year":"1996","unstructured":"Kifor O, Moore FD Jr., Wang P, Goldstein M, Vassilev P, Kifor I, Hebert SC, Brown EM (1996) Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 81:1598\u20131606","journal-title":"J Clin Endocrinol Metab"},{"key":"1699_CR5","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1073\/pnas.95.7.4040","volume":"95","author":"EF Nemeth","year":"1998","unstructured":"Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF (1998) Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A 95:4040\u20134045","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1699_CR6","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global O, (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69:1945\u20131953","journal-title":"Kidney Int"},{"key":"1699_CR7","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/ndt\/gfh966","volume":"20","author":"SM Moe","year":"2005","unstructured":"Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM (2005) Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transpl 20:2186\u20132193","journal-title":"Nephrol Dial Transpl"},{"key":"1699_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jama.2016.19456","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Bushinsky DA, Cunningham J, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Mix TC, Moe SM, Patel UD, Silver J, Spiegel DM, Sterling L, Walsh L, Chertow GM (2017) Effect of Etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA 317:146\u2013155","journal-title":"JAMA"},{"key":"1699_CR9","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","volume":"94","author":"M Fukagawa","year":"2018","unstructured":"Fukagawa M, Shimazaki R, Akizawa T, Evocalcet study g, (2018) Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 94:818\u2013825","journal-title":"Kidney Int"},{"key":"1699_CR10","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.2215\/CJN.0000000000000253","volume":"18","author":"T Shigematsu","year":"2023","unstructured":"Shigematsu T, Koiwa F, Isaka Y, Fukagawa M, Hagita K, Watanabe YS, Honda D, Akizawa T (2023) Efficacy and safety of Upacicalcet in hemodialysis patients with secondary hyperparathyroidism: a randomized placebo-controlled trial. Clin J Am Soc Nephrol 18:1300\u20131309","journal-title":"Clin J Am Soc Nephrol"},{"key":"1699_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0140-6736(17)31430-7","volume":"391","author":"JP Bilezikian","year":"2018","unstructured":"Bilezikian JP, Bandeira L, Khan A, Cusano NE (2018) Hyperparathyroidism. Lancet 391:168\u2013178","journal-title":"Lancet"},{"key":"1699_CR12","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1210\/jc.2008-2640","volume":"94","author":"C Marcocci","year":"2009","unstructured":"Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, Henzen C, Cheng S, Sterling LR, Lu J, Peacock M (2009) Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab 94:2766\u20132772","journal-title":"J Clin Endocrinol Metab"},{"key":"1699_CR13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s00774-016-0797-0","volume":"35","author":"Y Takeuchi","year":"2017","unstructured":"Takeuchi Y, Takahashi S, Miura D, Katagiri M, Nakashima N, Ohishi H, Shimazaki R, Tominaga Y (2017) Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism. J Bone Miner Metab 35:616\u2013622","journal-title":"J Bone Miner Metab"},{"key":"1699_CR14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00774-020-01097-y","volume":"38","author":"Y Takeuchi","year":"2020","unstructured":"Takeuchi Y, Nishida Y, Kondo Y, Imanishi Y, Fukumoto S (2020) Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study. J Bone Miner Metab 38:687\u2013694","journal-title":"J Bone Miner Metab"},{"key":"1699_CR15","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM et al (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516\u20131525","journal-title":"N Engl J Med"},{"key":"1699_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1542-4758.2009.00397.x","volume":"14","author":"Y Gincherman","year":"2010","unstructured":"Gincherman Y, Moloney K, McKee C, Coyne DW (2010) Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients. Hemodial Int 14:68\u201372","journal-title":"Hemodial Int"},{"key":"1699_CR17","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/j.bmcl.2018.04.055","volume":"28","author":"H Miyazaki","year":"2018","unstructured":"Miyazaki H, Ikeda Y, Sakurai O, Miyake T, Tsubota R et al (2018) Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism. Bioorg Med Chem Lett 28:2055\u20132060","journal-title":"Bioorg Med Chem Lett"},{"key":"1699_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195316","volume":"13","author":"T Kawata","year":"2018","unstructured":"Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, Hisada Y, Yanagida T, Miyazaki H, Wada M, Akizawa T, Fukagawa M (2018) A novel calcimimetic agent, evocalcet (MT-4580\/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS ONE 13:e0195316","journal-title":"PLoS ONE"},{"key":"1699_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245785","volume":"16","author":"S Tokunaga","year":"2021","unstructured":"Tokunaga S, Kawata T (2021) The effect of evocalcet on vagus nerve activity of the gastrointestinal tract in miniature pigs. PLoS ONE 16:e0245785","journal-title":"PLoS ONE"},{"key":"1699_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/science.ado1868","volume":"385","author":"F Liu","year":"2024","unstructured":"Liu F, Wu CG, Tu CL, Glenn I, Meyerowitz J, Kaplan AL, Lyu J, Cheng Z, Tarkhanova OO, Moroz YS, Irwin JJ, Chang W, Shoichet BK, Skiniotis G (2024) Large library docking identifies positive allosteric modulators of the calcium-sensing receptor. Science 385:eado1868","journal-title":"Science"},{"key":"1699_CR21","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1172\/JCI10523","volume":"107","author":"Y Imanishi","year":"2001","unstructured":"Imanishi Y, Hosokawa Y, Yoshimoto K, Schipani E, Mallya S, Papanikolaou A, Kifor O, Tokura T, Sablosky M, Ledgard F, Gronowicz G, Wang TC, Schmidt EV, Hall C, Brown EM, Bronson R, Arnold A (2001) Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest 107:1093\u20131102","journal-title":"J Clin Invest"},{"key":"1699_CR22","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s00774-020-01169-z","volume":"39","author":"N Hayashi","year":"2021","unstructured":"Hayashi N, Imanishi Y, Hirakawa T, Kobayashi I, Tateishi T, Miyaoka D, Nagata Y, Mori K, Morioka T, Inoue A, Harada K, Inaba M, Emoto M (2021) Etelcalcetide decreases the PTH-calcium setpoint without changing maximum and minimum PTH secretion in mice with primary hyperparathyroidism. J Bone Miner Metab 39:430\u2013438","journal-title":"J Bone Miner Metab"},{"key":"1699_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00223-011-9490-4","volume":"89","author":"Y Imanishi","year":"2011","unstructured":"Imanishi Y, Kawata T, Kenko T, Wada M, Nagano N, Miki T, Arnold A, Inaba M (2011) Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism. Calcif Tissue Int 89:29\u201335","journal-title":"Calcif Tissue Int"},{"key":"1699_CR24","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1359\/jbmr.2002.17.9.1656","volume":"17","author":"Y Imanishi","year":"2002","unstructured":"Imanishi Y, Hall C, Sablosky M, Brown EM, Arnold A (2002) A new method for in vivo analysis of parathyroid hormone-calcium set point in mice. J Bone Miner Res 17:1656\u20131661","journal-title":"J Bone Miner Res"},{"key":"1699_CR25","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1530\/eje.1.02007","volume":"153","author":"T Kawata","year":"2005","unstructured":"Kawata T, Imanishi Y, Kobayashi K, Kenko T, Wada M, Ishimura E, Miki T, Nagano N, Inaba M, Arnold A, Nishizawa Y (2005) Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism. Eur J Endocrinol 153:587\u2013594","journal-title":"Eur J Endocrinol"},{"key":"1699_CR26","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1517\/17460440903022743","volume":"4","author":"Y Imanishi","year":"2009","unstructured":"Imanishi Y, Inaba M, Kawata T, Nishizawa Y (2009) Animal models of hyperfunctioning parathyroid diseases for drug development. Expert Opin Drug Discov 4:727\u2013740","journal-title":"Expert Opin Drug Discov"},{"key":"1699_CR27","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/0002-9343(79)90446-7","volume":"66","author":"EM Brown","year":"1979","unstructured":"Brown EM, Gardner DG, Brennan MF, Marx SJ, Spiegel AM, Attie MF, Downs RW Jr., Doppman JL, Aurbach CD (1979) Calcium-regulated parathyroid hormone release in primary hyperparathyroidism: studies in vitro with dispersed parathyroid cells. Am J Med 66:923\u2013931","journal-title":"Am J Med"},{"key":"1699_CR28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1210\/jcem-54-1-172","volume":"54","author":"EM Brown","year":"1982","unstructured":"Brown EM, Wilson RE, Eastman RC, Pallotta J, Marynick SP (1982) Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab 54:172\u2013179","journal-title":"J Clin Endocrinol Metab"},{"key":"1699_CR29","doi-asserted-by":"publisher","first-page":"51739","DOI":"10.1074\/jbc.M406164200","volume":"279","author":"HC Mun","year":"2004","unstructured":"Mun HC, Franks AH, Culverston EL, Krapcho K, Nemeth EF, Conigrave AD (2004) The Venus fly trap domain of the extracellular Ca2+ -sensing receptor is required for L-amino acid sensing. J Biol Chem 279:51739\u201351744","journal-title":"J Biol Chem"},{"key":"1699_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1124\/jpet.113.204834","volume":"346","author":"S Walter","year":"2013","unstructured":"Walter S, Baruch A, Dong J, Tomlinson JE, Alexander ST, Janes J, Hunter T, Yin Q, Maclean D, Bell G, Mendel DB, Johnson RM, Karim F (2013) Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther 346:229\u2013240","journal-title":"J Pharmacol Exp Ther"},{"key":"1699_CR31","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1523-1755.2005.67103.x","volume":"67","author":"M Colloton","year":"2005","unstructured":"Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D (2005) Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 67:467\u2013476","journal-title":"Kidney Int"},{"key":"1699_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/ejendo\/lvae122","volume":"191","author":"P Kaur","year":"2024","unstructured":"Kaur P, Hegde D, Singh P, Gautam D, Sarin D, Bhadada S, Mithal A (2024) mRNA expression of vitamin D receptor, calcium-sensing receptor, cyclin D1, and PTH in symptomatic and asymptomatic primary hyperparathyroidism. Eur J Endocrinol 191:457\u2013462","journal-title":"Eur J Endocrinol"},{"key":"1699_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s41100-024-00529-z","volume":"10","author":"N Nagano","year":"2024","unstructured":"Nagano N, Ishikawa T, Yamaguchi M, Katsuragi Y, Miya M, Tamei N, Muto S, Tsutsui T, Ogawa T, Ito K (2024) Long\u2011term treatment of evocalcet in hemodialysis patients with secondary hyperparathyroidism: a five\u2011year prospective cohort study in 147 Japanese patients. Renal Replace Ther 10:13","journal-title":"Renal Replace Ther"},{"key":"1699_CR34","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1210\/me.2005-0116","volume":"19","author":"SM Mallya","year":"2005","unstructured":"Mallya SM, Gallagher JJ, Wild YK, Kifor O, Costa-Guda J, Saucier K, Brown EM, Arnold A (2005) Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model of primary hyperparathyroidism. Mol Endocrinol 19:2603\u20132609","journal-title":"Mol Endocrinol"},{"key":"1699_CR35","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1097\/01.ASN.0000141016.20133.33","volume":"15","author":"M Mizobuchi","year":"2004","unstructured":"Mizobuchi M, Hatamura I, Ogata H, Saji F, Uda S, Shiizaki K, Sakaguchi T, Negi S, Kinugasa E, Koshikawa S, Akizawa T (2004) Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 15:2579\u20132587","journal-title":"J Am Soc Nephrol"},{"key":"1699_CR36","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202300209R","volume":"37","author":"T Saito","year":"2023","unstructured":"Saito T, Mizobuchi M, Sakai M, Kawata T, Kitayama T, Kato T, Suzuki T, Ogata H, Koiwa F, Honda H (2023) Effects of evocalcet on parathyroid calcium-sensing receptor and vitamin D receptor expression in uremic rats. FASEB J 37:e23094","journal-title":"FASEB J"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-026-01699-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-026-01699-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-026-01699-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:10:28Z","timestamp":1780945828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-026-01699-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1699"],"URL":"https:\/\/doi.org\/10.1007\/s00774-026-01699-y","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"12 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YI received lecture fees from Kyowa Kirin Co., Ltd., Tokyo, Japan. Other authors have no conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}